ID
Firm cautions Nigerian government over sale of national assets
Agusto Consulting has cautioned the federal government over its plan to relinquish national assets to private hands, saying, the risk involved is unquantifiable. Agusto Consulting, in a report titled “Rethinking Nigeria’s Models for Infrastructure Development,” noted that, the benefits of relinquishing control to the private sector are glaring, but remain difficult to implement. Noting that the federal government’s handing off certain critical assets of the country that have been dormant over the years will positively impact on the country’s budgetary allocation, but added that this decision has caveats and risks associated with operating models that involve private sector participation regardless of the levels of participation. “First is the high level of corruption in the country and the...
Ex-President Obasanjo, catfish farmers brainstorm on how to move aquaculture forward
Former President, Chief Olusegun Obasanjo and Catfish farmers in the country on Saturday met to brainstorm and strategize for better productivity in the industry. The farmers, under the aegis of the Catfish Farmers Association of Nigeria (CAFAN) met with the former President, who is a founding member of the body at the boardroom of Olusegun Obasanjo Presidential Library (OOPL) Abeokuta. Obasanjo who expressed satisfaction in returning to the association, after what he described as an interregnum, assured that the industry would be at enviable heights in no distance future if they all worked together as a body. Obasanjo said, “I started poultry farmers association and as a result of its achievements, that was why I began the catfish association too. What put me off, was that I was arrested,...
Nigeria ratifies membership of AfCFTA
The Federal Executive Council, FEC, on Wednesday ratified Nigeria’s membership of the Africa Continental Free Trade Area, AfCFTA, as the implementation of the agreement formally takes-off on January 1, 2021. This is as the Council has approved N62.7 billion for the construction of Kano-Dawakin-Tofa-Gwarzo-Dariyo road in Kano. Briefing State House correspondents at the end of the 23rd virtual FEC meeting presided over by President Muhammadu Buhari at the Council Chamber, Presidential Villa, Abuja, the Minister of Information and Culture, Alhaji Lai Mohammed, said whereas the implementation of the agreement was initially scheduled to commence in July, this year, the plan was stalled by the spread of COVID-19. Alhaji Mohammed, who briefed on behalf of the Minister of Industry, Trade and Inves...
US election: Republicans hold back Democrats, narrowing path to Senate control
The battle for power in the Senate tightened into Wednesday as Democrats picked up a seat in Colorado, but suffered a setback in Alabama, and Republicans held their own in high-profile races in South Carolina, Iowa, Texas and Kansas, dramatically narrowing the political map. Republicans fought to retain their Senate majority by turning back a surge of Democrats challenging allies of President Donald Trump, and the Democrats’ various paths to seizing control were growing more limited. With several contests still too early to call, and one Georgia race heading to a January runoff, the final verdict is expected to drag on. Democrats gained a seat when ex-Gov. John Hickenlooper ousted GOP Sen. Cory Gardner in Colorado, a must-win to flip the Senate, but couldn’t hold on in Alabama, where forme...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
